Navigation Links
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Date:11/29/2007

ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)announced today that the Circulatory System Devices Advisory Panel to the U.S. Food and Drug Administration (FDA) recommended approval for the XIENCE(TM) V Everolimus Eluting Coronary Stent System. XIENCE V is a next-generation drug eluting stent intended for use in the treatment of coronary artery disease.

The FDA advisory committee voted to recommend the XIENCE V stent system for approval with conditions related to post-marketing study requirements and language related to dual antiplatelet therapy. The FDA is not required to, but usually follows the recommendations of its advisory committees.

"The clinical and angiographic benefits of the XIENCE V stent compared to the most widely used drug eluting stent available in the U.S. have been consistent and significant across the SPIRIT trials," said Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation, New York and principal investigator of the SPIRIT III clinical trial. "The robust body of safety and efficacy data support approval of XIENCE V as an important new technology that will enhance the lives of millions of patients with heart disease."

Abbott filed its Premarket Approval (PMA) submission for XIENCE V with the FDA on June 1, 2007. The PMA for XIENCE V is the first to include data demonstrating superiority of one drug eluting stent over another in the primary endpoint of in-segment late loss in a randomized controlled head-to-head trial with a market leading product.

"The outcome of today's advisory committee meeting is very encouraging," said John M. Capek, Ph.D., executive vice president, Medical Products, Abbott. "We look forward to bringing this important new treatment for coronary artery disease to physicians and patients in the U.S."

XIENCE V was launched in Europe and other international markets in 2006. XIENCE V is currently an investigational
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 “After my mom’s stroke, ... had a stroke and loss the use of his left side. ... design a way to help people like them enjoy eating again,” ... a prototype for the PATRICIA CAROL HALL PLATE (P C H ... offers a more ergonomic way to eat for individuals who suffer ...
(Date:7/12/2014)... July 12, 2014 Wright & Schulte LLC ... Orthopedics , Inc., a subsidiary of Johnson & Johnson, on ... chronic pain after receiving a metal-on-metal DePuy Pinnacle hip replacement ... remove the artificial hip implant. The DePuy hip lawsuit was ... District of Texas (Case No. 3:14-cv-2427) where DePuy Pinnacle ...
(Date:7/12/2014)... 2014 Dubai is buzzing with the ... heading to the UAE. The National Basketball Association’s ... in the UAE from 28-31 October to lead the ... diabetes awareness. The event is being organized by Maven ... management company based in Dubai. The announcement was made ...
(Date:7/12/2014)... 12, 2014 Floor-grade instrument ... 4.1 out of 5. This above-average score represents ... underpinning buyer negotiation power over the three years ... Son, “during the period, surging demand for healthcare ... with new product development, have placed upward pressure ...
(Date:7/11/2014)... Recently, DressyQuinceanera.com, a well-known wedding dress manufacturer and retailer, ... its online category. Furthermore, the firm has announced that ... up to 62% off. , The brand new Quinceanera ... of quality and style. All items in the new ... for the company’s other items: lace evening dresses, short ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2
... Nov. 8 Synova Healthcare Group,Inc. (OTC Bulletin Board: ... its Today(R) Sponge non-hormonal contraceptive,product in Hong Kong and ... Hong Kong. This represents an important milestone for the,Company, ... made the Today(R) Sponge,available to women outside North America. ...
... Nov. 8, 2007 An Israeli-Jordanian-U.S. cooperative project aimed ... neighboring southern cities of Aqaba in Jordan and Eilat ... Hebrew University of Jerusalem together with scientists from the ... Research Institute of Reno, Nevada, in the US. ...
... determined how cardiac cells die just as emergency treatments restore blood ... puzzled doctors who are able to relieve pain in patients suffering ... renewed rush of blood. , The discovery may lead to ... the stoppage of blood flow and resulting loss of oxygen to ...
... , The topic of cancer prevention is covered ... with apparently conflicting information and complex scientific research that ... The American Association for Cancer Research (AACR) and Susan ... communication between the scientific research community and journalists who ...
... New Law and New Regulations Could Hold the Key to ... Reducing Rising Skin Cancer Rates, NEW YORK, ... of skin cancer will be diagnosed in the United States in,2007. While ... stress that prevention is still the best,medicine. In fact, dermatologists are hopeful ...
... NEW YORK, Nov. 8 The changing of the ... to health clubs for a,healthy dose of indoor exercise. ... beneficial activities a person can do to improve one,s ... the hidden dangers of,exercise -- bothersome skin conditions that ...
Cached Medicine News:Health News:Today(R) Sponge to be Distributed in Hong Kong and Macau 2Health News:Today(R) Sponge to be Distributed in Hong Kong and Macau 3Health News:'Beam of Light' is ray of hope for Israeli-Jordanian cooperation 2Health News:Mitochondria send death signal to cardiac cells, study shows 2Health News:Mitochondria send death signal to cardiac cells, study shows 3Health News:Skin Cancer Prevention Update: 2Health News:Skin Cancer Prevention Update: 3Health News:Skin Cancer Prevention Update: 4Health News:Skin Cancer Prevention Update: 5Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 2Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 3Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 4Health News:Dermatologists Warn Fitness Enthusiasts: Don't Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity 5
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Data to be presented November 2 at the American Society of Nephrology ... ... Calif., Oct. 16 ,Exelixis, Inc. (Nasdaq: EXEL ) announced that a ... of reducing proteinuria,compared with placebo in patients with proteinuria associated with diabetic,nephropathy. ...
... Concentra, the largest,occupational health care provider with ... to educate America,s workforce about the flu, how ... The company expects to vaccinate,nearly 300,000 people across ... lost productivity. Concentra Medical Centers offers flu ...
Cached Medicine Technology:Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy 2Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy 3Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy 4Concentra Offers Flu Vaccines to Keep America Working 2
... Combining exceptional new features ... XLTEKs latest innovation, the ... biphasic intracranial stimulation up ... 300 volts and transcranial ...
... high-volume analyzer that builds upon the field-proven ... and the latest Olympus technological advances. The ... with up to 147 on-board chemistries and ... Choose from Olympus 122 test menu, including ...
... e is designed for the ... laboratories and hospitals. Automate and consolidate ... reliability and Olympus 122 test menu, ... specific proteins, esoteric chemistries and tests ...
... is intended for the quantitative determination of Erythropoietin ... for in vitro diagnostic use, as an aid ... the advent of the administration of recombinant erythropoietin ... cell mass, an erythropoietin assay may be used ...
Medicine Products: